Vaxcyte (PCVX) Preferred Stock Liabilities (2019 - 2020)
Vaxcyte (PCVX) reported Preferred Stock Liabilities of $80.2 million for Q1 2020, up 112.76% year-over-year from $37.7 million in Q2 2019, and down 49.98% quarter-over-quarter from $160.3 million in Q4 2019.
Vaxcyte (PCVX) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Vaxcyte (PCVX) has 2 years of Preferred Stock Liabilities data on file, last reported at $80.2 million in Q1 2020.
- Preferred Stock Liabilities for Q1 2020 came in at $80.2 million, up 112.76% year-over-year; the trailing twelve-month figure through Mar 2020 was $80.2 million (up 112.76% YoY), and the FY2019 annual result was $160.3 million, up 325.32% from the prior year.
- Preferred Stock Liabilities eased to $80.2 million in Q1 2020 per PCVX's latest filing, from $160.3 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $160.3 million in Q4 2019 and troughed at $25.0 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Vaxcyte | 6.34 Bn | 6.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 80.19 Mn |
| Dec 31, 2019 | 160.31 Mn |
| Sep 30, 2019 | 24.97 Mn |
| Jun 30, 2019 | 37.69 Mn |
| Mar 31, 2019 | 37.69 Mn |